Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.

Name: Αlpha¹ Rigor Record — Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Item: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Rating: 100
Author: Αlpha¹

Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S, BARACK-D Investigators, BARACK-D Investigators, Regional coordinating centre teams

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 0 high issues for “Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized trial. The methodology is rigorous, with clear randomization, blinding, power calculation, and comprehensive reporting of demographics, ethics, resources, statistics, data/code availability, and limitations. The main weaknesses are minor reporting inconsistencies and the significant under-recruitment, which is transparently acknowledged.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered all eight dimensions; several sub-criteria were marked not applicable (e.g., animal-related, cell line, and replication criteria) due to the human trial design. The statistics verification covered only a subset of tests (those with test statistics/df or effect estimates with CIs); the remaining tests were not machine-verifiable and are not confirmed.

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Recomputed 19 tests: 19 consistent, 0 inconsistent; 4 recomputed directly from the reported test statistics, 15 via agent-written checks.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior research on CKD, cardiovascular risk, and MRAs, including finerenone trials, and acknowledges uncertainties regarding spironolactone. The rationale for the trial is clearly linked to the need to establish whether spironolactone provides similar benefits to finerenone. Limitations of prior work (e.g., finerenone trials excluding non-diabetic and non-albuminuric patients) are explicitly addressed.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the trial.

Evidence

direct quote[Introduction, paragraph 1-4]

“The nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardiorenal protection for people with CKD and diabetes, but there is uncertainty if the steroidal MRA, spironolactone, provides the same protection.”